Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Tidbits From The Fourth Quarter Calls, In Brief

Feb 10 2003

• By The Pink Sheet

Related Content

Oncologic Accelerated Approval Phase IV Studies For 7 Drugs To Be Reviewed

Feb 03 2003

Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March

Jan 13 2003

Lilly Forteo “Customer Care” Program Provides One Month Of Therapy Free

Jan 13 2003

Iressa User Fee Date Pushed To May; Will Advisory Cmte. Take Second Look?

Jan 13 2003

Allergan Restasis Launch Set For April Following Approval Of Dry Eye Drug

Jan 06 2003

Lilly Strattera Is First ADHD Agent With Adult Indication, Full-Scale Launch

Dec 02 2002

Schwarz Omeprazole Launch Is Limited By Manufacturing Capacity

Dec 16 2002

Serono Rebif: 80% Of Rxs Are Switches, Efficacy Is Main Marketing Message

Dec 09 2002

Watson Oxytrol Approval Expected In 2003; Patch Is “Not Approvable” At FDA

Apr 01 2002

Lilly Xigris Marketing Plans Stress Journal Articles, “Sharpened” Messages

Nov 18 2002

Mylan Generic Isotretinoin Price Will Be 90% Of Roche Accutane AWP

Nov 18 2002

Wyeth Cost-Cutting Will Spare Effexor, Manufacturing Investments

Nov 25 2002

Wyeth Zosyn Inventory Allocation Program Likely To Last Through 2002

Mar 04 2002

Barr Eyes Oncology For Branded Acquisitions Beyond Women’s Health

Feb 04 2002

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window